

10088726, 100102

JC10 Rec'd PCT/PTO 22 MAR 2002

FORM PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 6235-62514
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371			U.S. APPLICATION NO. (If known, see 37 C.F.R. § 1.55) 10/088726
INTERNATIONAL APPLICATION NO. PCT/JP00/09408	INTERNATIONAL FILING DATE 28 December 2000	PRIORITY DATE CLAIMED 28 December 1999	
TITLE OF INVENTION NOVEL GUANOSINE TRIPHOSPHATE-BINDING PROTEIN-COUPLED RECEPTORS AND GENES THEREOF, AND PRODUCTION AND USES THEREOF			
APPLICANT(S) FOR DO/EO/US			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. § 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input checked="" type="checkbox"/> An unsigned oath or declaration of the inventor(s) (35 U.S.C. § 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 and the Recordal fee of \$40.00 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Abstract on a separate page. <input checked="" type="checkbox"/> Sequence Listing (48 pages) (Paper Copy and Diskette), and Statement in Compliance. <input type="checkbox"/> Preliminary Examination Report. <input checked="" type="checkbox"/> International Search Report. <input type="checkbox"/> Copies of References Cited. 			



10088726, 100102

SLR:dm 03/22/02 6235-62514 105442.doc

EXPRESS MAIL LABEL NO. EV059538934US

DATE OF DEPOSIT: March 22, 2002

JC13 Rec'd PCT/PTO 22 MAR 2002

U.S. APPLICATION NO. (If known, see 37 C.F.R. § 1.51) 10/088726		INTERNATIONAL APPLICATION NO. PCT/JP00/09408		ATTORNEY'S DOCKET NUMBER 6235-62514	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS (PTO USE ONLY)	
BASIC NATIONAL FEE (37 C.F.R. §§ 1.492(a)(1)-(5)): Neither International Preliminary Examination fee (37 C.F.R. § 1.482) nor International Search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,040.00 International Preliminary Examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International Preliminary Examination fee (37 C.F.R. § 1.482) not paid to USPTO but International Search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO as an International Searching Authority \$740.00 International Preliminary Examination fee paid to USPTO (37 C.F.R. § 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International Preliminary Examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	890.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	27 - 20 =	7	x \$18.00	\$	126.00
Independent Claims	2 - 3 =	0	x \$84.00	\$	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1,016.00
<input type="checkbox"/> Reduction of 1/2 for filing by small entity. Small entity status is claimed for this application.				\$	0.00
SUBTOTAL =				\$	1,016.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 C.F.R. §§ 1.492(f)).				\$	0.00
TOTAL NATIONAL FEE =				\$	1,016.00
Fee for recording the enclosed assignment (37 C.F.R. § 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.				\$	0.00
TOTAL FEES ENCLOSED =				\$	1,016.00
				REFUND →	\$
				CHARGE →	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,016.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. <u>02-4550</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input checked="" type="checkbox"/> Please return the enclosed postcard to confirm that the items listed above have been received.</p>					
<p>NOTE: Where an appropriate time limit under 37 C.F.R. § 1.494 or § 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
KLARQUIST SPARKMAN, LLP One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, OR 97204-2988			SIGNATURE <u>Sheree Lynn Rybak, Ph.D.</u> NAME 47,913 REGISTRATION NUMBER		

cc: Docketing

SLR:dm 03/22/02 6235-62514 105686.doc

PATENT
Attorney's Matter No. 6235-62514

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Matsumoto et al.

Art Unit: _____

Application No. _____

Filed: Herewith

For: NOVEL GUANOSINE TRIPHOSPHATE-
BINDING PROTEIN-COUPLED RECEPTORS
AND GENES THEREOF, AND PRODUCTION
AND USES THEREOF

Examiner: _____

Date: March 22, 2002

STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)


COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing." No new matter has been added.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446